Standard of care in NSCLC requires testing for ALK, BRAF, EGFR, ERBB2, KRAS, MET, NTRK, RET, ROS1.

Download Study

Pre-treatment imaging

Post-treatment imaging
*Representative patient images

Patient Case

Clinical presentation
  • 68-year-old male non-smoker initially presented with severe cough and nausea
  • Evaluation showed lung mass, and subsequent PET scan identified multiple metastatic lesions; patient was diagnosed with advanced NSC
  • While waiting for single-gene tissue testing results to be returned, guideline-recommended genomic testing with Guardant360® LDT liquid biopsy identified BRAF V600E in 7 days
  • The patient was put on BRAF/MET inhibitor combination and achieved a partial response

You might also be interested in